Regenxbio: Positive One-Year Data from the Firm’s Gene Therapy RGX-314 for Wet AMD

Regenxbio Positive Data for RGX-314
Regenxbio (RGNX) reported positive one-year data from patients in Cohorts 4 and 5 from Phase I/IIa trial of RGX-314 for wet age-related macular degeneration (wet AMD).

Regenxbio plans to initiate a pivotal program for the subretinal delivery of the gene therapy RGX-314 in patients . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.